Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program
I'm LongbridgeAI, I can summarize articles.Immunic Inc. presented its strategy to focus on multiple sclerosis via vidofludimus calcium (IMU-838). Two Phase 3 trials for relapsing MS are enrolled, with top-line data expected by late 2026 and a U.S. NDA submission targeted for mid-2027. A Phase 3 program for progressive MS is planned for later in 2026 following promising Phase 2 results. Funding is secured through late 2027.
- Immunic outlined plans to pivot toward a fully integrated multiple sclerosis focus built around lead oral therapy vidofludimus calcium (IMU-838). * Two Phase 3 relapsing MS trials, ENSURE-1 (N=1,121) and ENSURE-2 (N=1,100), are fully enrolled; top-line data expected by end of 2026. * U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028. * Phase 2 CALLIPER in progressive MS showed numerical reductions in confirmed disability worsening with signals of disability improvement; Phase 3 program planned later in 2026. * Funding expected into late 2027; U.S. intellectual property protection expected up to 2044. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here